Braidwell LP Makes New $3.02 Million Investment in Verve Therapeutics, Inc. (NASDAQ:VERV)

Braidwell LP bought a new stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 623,980 shares of the company’s stock, valued at approximately $3,020,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in VERV. Nisa Investment Advisors LLC increased its holdings in shares of Verve Therapeutics by 908.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 7,714 shares of the company’s stock valued at $38,000 after acquiring an additional 6,949 shares during the last quarter. Creative Planning bought a new stake in Verve Therapeutics during the third quarter worth approximately $50,000. PFG Investments LLC acquired a new position in Verve Therapeutics during the third quarter valued at approximately $53,000. Daiwa Securities Group Inc. raised its position in shares of Verve Therapeutics by 89.8% in the second quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company’s stock valued at $59,000 after purchasing an additional 5,723 shares during the period. Finally, Cornercap Investment Counsel Inc. lifted its stake in shares of Verve Therapeutics by 13.5% in the second quarter. Cornercap Investment Counsel Inc. now owns 14,956 shares of the company’s stock worth $73,000 after buying an additional 1,778 shares during the last quarter. Institutional investors and hedge funds own 97.11% of the company’s stock.

Verve Therapeutics Stock Up 8.9 %

Shares of VERV stock opened at $5.78 on Friday. Verve Therapeutics, Inc. has a 1 year low of $4.30 and a 1 year high of $19.34. The firm’s fifty day simple moving average is $5.36 and its 200 day simple moving average is $5.60.

Verve Therapeutics (NASDAQ:VERV) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.11. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The company had revenue of $6.87 million for the quarter, compared to the consensus estimate of $2.75 million. During the same quarter in the previous year, the firm posted ($0.72) EPS. The business’s revenue was up 120.2% compared to the same quarter last year. On average, analysts anticipate that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Canaccord Genuity Group raised their target price on shares of Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. HC Wainwright lowered their price target on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada dropped their price objective on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.